ENTA’s R&D expenses are projected to average $30M per quarter
i didnt hear the call but i can't imagine they guided for this. their antibiotic program is funded externally until ph 2 and they are only planning on a possible IND for preclinical HCV candidate later this year
ENTA’s cash balance at 6/30/14 was $137.6M, an increase of about $36M relative to the 3/31/14 balance thanks to the $40M in milestone payments received from ABBV for the 3-DAA submission in the US and EU.
Adding in the expected $150M in milestone payments from ABBV for FDA and EMA approval of the 3-DAA HCV regimen (#msg-100940717), and the likelihood of a $15M milestone payment from NVS for starting a phase-2b trial of EDP-239 (#msg-105063800), absent a glitch ENTA could soon be rolling in almost $300M of cash.
Market Data 
Markets 
AI
